On Wednesday, shares of BioNTech SE (NASDAQ:BNTX) marked $86.86 per share versus a previous $93.00 closing price. With having a -6.60% loss, an insight into the fundamental values of BioNTech SE, investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. BNTX showed a rise of 156.38% within its YTD performance, with highs and lows between $12.52 – $105.00 during the period of 52 weeks, compared to the simple moving average of 58.26% in the period of the last 200 days.
Berenberg equity researchers changed the status of BioNTech SE (NASDAQ: BNTX) shares to a “Buy” rating in the report published on August 3rd, 2020. Other analysts, including BofA Securities, also published their reports on BNTX shares. BofA Securities repeated the rating from the previous report, marking BNTX under “Buy” rating, in the report published on July 21st, 2020. Additionally, BNTX shares got another “Neutral” rating from H.C. Wainwright. On May 19th, 2020, H.C. Wainwright Upgrade an Buy rating and increased its price target from $48 to $69. On the other hand, BofA/Merrill Downgrade the “Neutral” rating for BNTX shares, as published in the report on April 28th, 2020. JP Morgan seems to be going bullish on the price of BNTX shares, based on the price prediction for BNTX, indicating that the shares will jump from $23 to $33, giving the shares “Neutral” rating based on their report from March 18th, 2020. Another “Neutral” rating came from H.C. Wainwright, providing a prediction for $33 price target according to the report published in March 9th, 2020.
[bold-text]BioNTech SE (BNTX) Analysis[/bold-text]
The present dividend yield for BNTX owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -3.70%, hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of BioNTech SE (BNTX) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 2.90 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while BNTX is currently recording an average of 3.40M in volumes. The volatility of the stock on monthly basis is set at 5.67%, while the weekly volatility levels are marked at 5.89%with 0.73% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $80.05, indicating growth from the present price of $86.86, which can represent yet another valuable research and analysis points that can help you decide whether to invest in BNTX or pass.
[bold-text]What to Look for When Analyzing BioNTech SE Shares?[/bold-text]
BioNTech SE (BNTX) is based in the Germany and it represents one of the well-known company operating with Healthcare sector. If you wish to compare BNTX shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for BioNTech SE, while the value 11.91 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -1.20 is supported by the yearly EPS growth of -300.50%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 1.26%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 11.50% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.
[bold-text]Are Institutional Investors Increasing Stakes in BNTX Shares?[/bold-text]
It appears that more than several institutional investors and hedge funds decided to increase stakes in BNTX in the recent period. That is how Fidelity Management & Research Co now has an increase position in BNTX by 1,338.63% in the first quarter, owning 10.19 million shares of BNTX stocks, with the value of $705.75 million after the purchase of an additional 9,485,666 shares during the last quarter. In the meanwhile, Redmile Group LLC also increased their stake in BNTX shares changed 1,703.27% in the first quarter, which means that the company now owns 3.07 million shares of company, all valued at $212.48 million after the acquisition of additional 2,898,964 shares during the last quarter.
PRIMECAP Management Co. acquired a new position in BioNTech SE during the first quarter, with the value of $191.96 million, and Artisan Partners LP increased their stake in the company’s shares by — in the first quarter, now owning 1,551,278 shares valued at $107.39 million after the acquisition of the additional 1.55 million shares during the last quarter. In the end, Janus Capital Management LLC increased their position by — during the first quarter, now owning 1.17 million BNTX shares, now holding the value of $80.94 million in BNTX with the purchase of the additional 1,169,133 shares during the period of the last quarter. At the present, 11.50% of BNTX shares are in the ownership of institutional investors.